Carisma Therapeutics Ownership | Who Owns Carisma Therapeutics?
Carisma Therapeutics Ownership Summary
Carisma Therapeutics is owned by 9.53% institutional investors, 27.76% insiders, and 62.71% retail investors. Merck is the largest institutional shareholder, holding 3.53% of CARM shares.
CARM Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Carisma Therapeutics | 9.53% | 27.76% | 62.71% |
| Sector | Healthcare Stocks | 487.91% | 11.08% | -398.99% |
| Industry | Biotech Stocks | 306.69% | 11.10% | -217.79% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Merck | 1.47M | 3.53% | $576.92K |
| Blackrock funding, inc. /de | 336.79K | 0.81% | $131.89K |
| Gts securities | 50.12K | 0.12% | $19.65K |
| Empowered funds | 30.99K | 0.07% | $12.13K |
| Blodgett wealth advisors | 24.00K | 0.06% | $6.58K |
| Two sigma securities | 17.95K | 0.04% | $7.03K |
| Dynamic financial group | 15.35K | 0.04% | $4.21K |
| Union bancaire privee, ubp sa | 535.00 | 0.00% | $131.00 |
| Org partners | 200.00 | 0.00% | $54.00 |
| Carolina wealth advisors | 150.00 | 0.00% | $41.00 |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Merck | 1.47M | 0.27% | $576.92K |
| Blodgett wealth advisors | 24.00K | 0.00% | $6.58K |
| Dynamic financial group | 15.35K | 0.00% | $4.21K |
| Two sigma securities | 17.95K | 0.00% | $7.03K |
| Gts securities | 50.12K | 0.00% | $19.65K |
| Empowered funds | 30.99K | 0.00% | $12.13K |
| Org partners | 200.00 | - | $54.00 |
| Carolina wealth advisors | 150.00 | - | $41.00 |
| Stratos wealth partners | - | - | - |
| Baader bank aktiengesellschaft | - | - | - |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Gts securities | 50.12K | 0.00% | 50.12K |
| Two sigma securities | 17.95K | 0.00% | 6.34K |
| Raymond james financial | 75.00 | - | 75.00 |
| Carolina wealth advisors | 150.00 | - | - |
| National bank of canada /fi/ | 50.00 | - | - |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Aju ib investment | - | - | -718.33K |
| Barclays | - | - | -549.30K |
| Millennium management | - | - | -120.16K |
| Blackrock funding, inc. /de | 336.79K | - | -70.09K |
| Hrt financial lp | - | - | -36.90K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Gts securities | 50.12K | 0.00% | 50.12K | $19.65K |
| Raymond james financial | 75.00 | - | 75.00 | $29.00 |
Sold Out
| Holder | Change |
|---|---|
| Citigroup | -10.00 |
| Peoples bank/ks | -250.00 |
| Bank & trust | -525.00 |
| Federated hermes | -5.63K |
| Tower research capital llc (trc) | -7.83K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | 34 | -2.86% | 3,982,439 | -2.93% | 9 | 9.78% | 10 | -28.57% | 6 | - |
| Mar 31, 2025 | 36 | - | 5,576,157 | 16.58% | 13 | 10.13% | 14 | -6.67% | 6 | -14.29% |
| Dec 31, 2024 | 38 | 2.70% | 4,888,967 | -6.07% | 11 | 7.50% | 16 | 45.45% | 7 | -41.67% |
| Sep 30, 2024 | 37 | -24.49% | 5,205,020 | -14.78% | 12 | 5.80% | 11 | -60.71% | 12 | -7.69% |
| Jun 30, 2024 | 49 | -2.00% | 6,107,691 | -28.20% | 14 | 3.40% | 28 | 55.56% | 13 | -31.58% |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Oct 07, 2025 | Klichinsky Michael | Chief Scientific Officer | Sell | $14.48K |
| Oct 01, 2025 | Klichinsky Michael | Chief Scientific Officer | Sell | $42.41K |
| Oct 02, 2025 | Klichinsky Michael | Chief Scientific Officer | Sell | $50.86K |
| Oct 03, 2025 | Klichinsky Michael | Chief Scientific Officer | Sell | $31.08K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q4 | - | 4 |
| 2025 Q1 | - | - |
| 2024 Q4 | - | - |
| 2024 Q3 | - | - |
| 2024 Q2 | - | - |
CARM Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools